ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +3.66%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.36 per share when it actually produced earnings of $2.37, delivering a surprise of +0.42%. Over ...

Core Insights - Baxter International reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.60 per share, and down from $0.68 per share a year ago, representing an earnings surprise of -1.67% [1] - The company posted revenues of $2.81 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.28%, and down from $3.81 billion year-over-year [2] - Baxter has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $2.9 billion, and for the current fiscal year, it is $2.50 on revenues of $11.35 billion [7] - The estimate revisions trend for Baxter was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Baxter belongs, is currently in the bottom 26% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

SNDL Inc. (SNDL) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +125.00%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of +33.33%. Over the last four quarters, the compa ...

Core Insights - Utah Medical Products, Inc. (UTMD) experienced a 3% decline in share price following its earnings report for Q2 2025, contrasting with a 0.6% increase in the S&P 500 index during the same period [1] - The company reported earnings per share (EPS) of 94 cents, a 4% decrease from 98 cents in Q2 2024 [1] Financial Performance - Net sales were $10 million, down 4.3% from $10.4 million in the same quarter last year [2] - Income before tax decreased by 8.9% to $3.8 million, while net income fell 11.7% to $3.1 million compared to $3.5 million in Q2 2024 [2] Sales Trends - Domestic sales increased by 0.6% to $5.9 million, driven by a 10% rise in direct non-Filshie device sales and an 8% increase in Filshie device sales [3] - However, OEM domestic sales plummeted by 38% due to a significant drop in PendoTECH orders [3] - International sales dropped 10.5% to $4.1 million, with direct sales by subsidiaries falling 15.8% [4] Profitability Metrics - Gross profit margin contracted to 56.2% from 60.1% a year earlier, with gross profit declining 10.5% to $5.6 million [5] - Operating income fell 7.1% to $3.2 million, and the operating margin decreased to 32.1% from 33.1% [5] - Net income margin narrowed to 30.6% from 33.2%, influenced by a higher effective tax rate of 20.5% compared to 18% in the previous year [6] Expense Management - Total operating expenses decreased by 14.8% to $2.4 million, with general and administrative expenses dropping 13.6% to $1.7 million [7] - R&D spending saw a significant decline of 47.1% to $0.1 million following the completion of biopharma sensor validation [7] Capital Allocation - The company repurchased 64,988 shares at an average price of $53.67 and paid $1 million in dividends, which accounted for 33% of net income [8] - Cash and investments at the end of the quarter totaled $82.2 million, slightly down from $83 million at the end of 2024 [8] Management Insights - Management attributed revenue decline to the expected drop in PendoTECH sales but highlighted the strength of core direct sales, particularly in the U.S. [9] - Full-year 2025 results are expected to reflect continued weakness in PendoTECH sales, projected to be about $2 million lower than in 2024 [10] - The current trailing twelve-month (TTM) EBITDA stands at $18.6 million, with a target range of $16 million to $18 million for the year [10]

Company Performance - AtriCure reported a quarterly loss of $0.02 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.17 per share a year ago, resulting in an earnings surprise of +86.67% [1] - The company achieved revenues of $136.14 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.61% and showing a year-over-year increase from $116.27 million [2] - Over the last four quarters, AtriCure has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - AtriCure shares have increased approximately 8.7% since the beginning of the year, slightly outperforming the S&P 500's gain of 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $129.12 million, and for the current fiscal year, it is -$0.50 on revenues of $522.61 million [7] Industry Context - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of AtriCure's stock may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Exagen Inc. reported a quarterly loss of $0.18 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.16 per share a year ago [1] - The company posted revenues of $17.2 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.51%, and up from $15.06 million year-over-year [2] - Exagen shares have increased approximately 80.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] 分组2 - The earnings outlook for Exagen is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Exagen was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $16.5 million, and -$0.61 on revenues of $65.8 million for the current fiscal year [7] 分组3 - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, which may impact stock performance [8] - Cresco Labs Inc., another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +75%, with revenues projected at $163.86 million, down 11.1% from the previous year [9]

Core Viewpoint - Tilray Brands, Inc. reported quarterly earnings of $0.02 per share, surpassing the Zacks Consensus Estimate of a loss of $0.03 per share, marking an earnings surprise of +166.67% [1] - The company posted revenues of $224.54 million for the quarter ended May 2025, which was 6.46% below the Zacks Consensus Estimate and a decrease from $229.88 million year-over-year [2] Financial Performance - The earnings report indicates a significant improvement from a loss of $0.04 per share a year ago [1] - Over the last four quarters, Tilray Brands has exceeded consensus EPS estimates twice, but has not beaten revenue estimates during the same period [2] Stock Performance - Tilray Brands shares have declined approximately 48.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Tilray Brands is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $209.71 million, and for the current fiscal year, it is -$0.17 on revenues of $885.29 million [7] - The outlook for the Medical - Products industry, to which Tilray Brands belongs, is currently in the bottom 30% of Zacks industries, which may negatively impact stock performance [8]

Core Insights - ResMed is positioned to continue its earnings-beat streak, having surpassed earnings estimates in the last two quarters by an average of 3.04% [1][5] - The company reported earnings of $2.36 per share for the most recent quarter, slightly below the expected $2.37, but still achieved a surprise of 0.42% [2] - In the previous quarter, ResMed exceeded the consensus estimate of $2.30 per share by reporting $2.43, resulting in a surprise of 5.65% [2] Earnings Estimates and Predictions - Recent estimates for ResMed have been increasing, with a positive Earnings ESP of +5.16%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9] Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the only factor influencing stock price movements; thus, checking the Earnings ESP is crucial for investment decisions [10]

Company Overview - Valneva SE Sponsored ADR (VALN) shares increased by 17.4% to $7.32 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has gained 11.3% over the past four weeks, indicating a positive trend [1] Market Sentiment - The rise in VALN shares is attributed to positive market sentiment driven by recent regulatory successes and strong momentum in the biotech sector [2] - Investor confidence was bolstered by the European Medicines Agency (EMA) lifting age-based restrictions on Valneva's chikungunya vaccine, reflecting increasing regulatory support [2] Financial Expectations - Valneva is projected to report a quarterly loss of $0.27 per share, which is a year-over-year improvement of 27% [3] - Expected revenues for the upcoming quarter are $55.89 million, representing a 36.4% increase compared to the same quarter last year [3] Earnings Estimates - The consensus EPS estimate for Valneva has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the importance of monitoring future earnings updates [4] Industry Context - Valneva is categorized within the Zacks Medical - Products industry, which includes other companies like GE HealthCare Technologies (GEHC) [5] - GEHC shares increased by 1% to $77.25, with a 6.3% return over the past month, indicating a positive trend in the same industry [5] GE HealthCare Overview - GE HealthCare's consensus EPS estimate for the upcoming report is $0.91, reflecting a 9% decrease from the previous year [6] - GE HealthCare also holds a Zacks Rank of 3 (Hold), similar to Valneva [6]

Core Viewpoint - Boston Scientific (BSX) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1][6]. Earnings Performance - The company has a solid track record of surpassing earnings estimates, with an average surprise of 9.82% over the last two quarters [2]. - In the last reported quarter, Boston Scientific achieved earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.67 per share by 11.94% [3]. - For the previous quarter, the company reported earnings of $0.70 per share against an expectation of $0.65 per share, resulting in a surprise of 7.69% [3]. Earnings Estimates and Predictions - Recent estimates for Boston Scientific have been trending upward, indicating positive sentiment among analysts [6]. - The Zacks Earnings ESP for the company is currently +0.88%, suggesting increased bullishness regarding its near-term earnings potential [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a strong likelihood of another earnings beat [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8].